Table 1 Published data sets used for testing the approach
Name | Topic | Number of publications | Relevant publications (%) | Reference |
|---|---|---|---|---|
Appenzeller-Herzog_2020 | Wilson’s Disease | 3479 | 26 (0.75%) | [40] |
Bos_2018 | Cerebral small vessel disease and dementia | 5756 | 10 (0.18%) | [41] |
Donners_2021 | Emicizumab | 660 | 15 (2.27%) | [42] |
Jeyaraman_2021 | Osteoarthritis | 1194 | 96 (2.26%) | [43] |
Leenaars_2020 | Rheumatoid arthritis | 9543 | 792 (8.30%) | [44] |
Mejboom_2021 | TNFα-inhibitors and biosimilars | 2224 | 37 (1.66%) | [45] |
Muthu_2021 | Spine surgery | 3254 | 354 (10.88%) | [46] |
Oud_2018 | Borderline personality disorder | 1053 | 20 (1.90%) | [47] |
van_de_Schoot_2018 | PTSD | 6225 | 38 (0.61%) | [48] |
Wolters_2018 | Dementia and heart disease | 5038 | 19 (0.38%) | [49] |